B. Stewart

发表

Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting.

G. Amidon, D. Fleisher, B. H. Stewart, 1985, Methods in enzymology.

Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter

B. H. Stewart, L. Whitfield, Barbra H. Stewart, 2000, Pharmaceutical Research.

Improving the intestinal mucosal cell uptake of water insoluble compounds

G. Amidon, S. Pogany, B. Stewart, 1985 .

Reconversion of Fosphenytoin in the Presence of Intestinal Alkaline Phosphatase

C. Tenhoor, B. Stewart, 1995, Pharmaceutical Research.

Uptake of prodrugs by rat intestinal mucosal cells: mechanism and pharmaceutical implications.

G. Amidon, B. H. Stewart, R. K. Brabec, 1986, Journal of pharmaceutical sciences.

Gastrointestinal Transport of Peptide and Protein Drugs and Prodrugs

G. Amidon, B. H. Stewart, J. Bai, 1994 .

Evaluation of a Targeted Prodrug Strategy to Enhance Oral Absorption of Poorly Water-Soluble Compounds

O. H. Chan, B. H. Stewart, H. L. Schmid, 1998, Pharmaceutical Research.

Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution.

G. Amidon, D. Fleisher, B. H. Stewart, 1986, Journal of pharmaceutical sciences.

CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.

G. Amidon, J. Rhie, D. Oh, 1999, Journal of pharmaceutical sciences.

A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin Is the Underlying Cause of the Lack of Proportionality Between Increasing Dose and Drug Levels in Plasma

Paul R. Thompson, B. H. Stewart, P. Thompson, 1993, Pharmaceutical Research.

Percutaneous drug penetration: Choosing candidates for transdermal development

G. Flynn, Gordon L. Flynn, Barbra Stewart, 1988 .

Chapter 27. Ex vivo approaches to predicting oral pharmacokinetics in humans

Yi Wang, B. H. Stewart, Barbra H. Stewart, 2000 .

Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes.

B. H. Stewart, A. Gough, W. Bobrowski, 1996, Journal of pharmaceutical sciences.

Physicochemical and drug-delivery considerations for oral drug bioavailability

O. H. Chan, B. H. Stewart, Barbra H. Stewart, 1996 .

Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.

A. Doherty, M. Reily, B. H. Stewart, 1997, Journal of medicinal chemistry.

Absorption of Cam-2445, and NK1 neurokinin receptor antagonist: in vivo, in situ, and in vitro evaluations.

O. H. Chan, B. H. Stewart, H. L. Schmid, 1996, Journal of pharmaceutical sciences.

Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers

D. Fleisher, B. H. Stewart, H. Bockbrader, 1999, Pharmaceutical Research.

Comparison of Intestinal Permeabilities Determined in Multiple in Vitro and inSitu Models: Relationship to Absorption in Humans

O. H. Chan, H. W. Hamilton, B. Steinbaugh, 1995, Pharmaceutical Research.

Hydrophobicity of HIV Protease Inhibitors by Immobilized Artificial Membrane Chromatography: Application and Significance to Drug Transport

O. H. Chan, B. Tait, C. John, 1998, Pharmaceutical Research.

Discrimination between drug candidates using models for evaluation of intestinal absorption

O. H. Chan, D. Fleisher, B. H. Stewart, 1997 .